Medifast (MED) Tops Q3 EPS by 6c; Boosts FY16 Outlook

Medifast (NYSE: MED) reported Q3 EPS of $0.51, $0.06 better than the analyst estimate of $0.45. Revenue for the quarter came in at $68.6 versus the consensus estimate of $66.79 million.

GUIDANCE:

Medifast sees Q4 2016 EPS of $0.30-$0.33. Medifast sees Q4 2016 revenue of $63-66 million.

Medifast sees FY2016 EPS of $1.86-$1.89, versus prior guidance of $1.79-$1.84 and the consensus of $1.88. Medifast sees FY2016 revenue of $275-278 million, versus the consensus of $275.6 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• Lucid reports Q2 output, names new CFO and five other leaders